NEWS FROM SEDIA BIOSCIENCES
NIH Awards Sedia Biosciences $195,490 SBIR Grant for Rapid HIV-1 Incidence Assay
Phase I Grant to develop a rapid assay version of Sedia’s HIV-1 LAg-Avidity EIA could expand HIV incidence testing in resource constrained settings and provide additional patient information for improved case management.
Sedia Biosciences Launches Asanté DNA, A New DNA Specimen Collection Kit
New cost-effective method for collecting DNA specimens from oral and other biological fluids and tissue.
Sedia Biosciences to Present and Exhibit at 2014 International AIDS Conference
First Look of a New Rapid HIV Incidence Assay to be Presented at Conference; Commercial Exhibit to Showcase Products.
Sedia Biosciences Receives $1.0 Million NIH Grant for New HIV Diagnostic Assay
Project would expand application of Sedia’s HIV-1 LAg-Avidity EIA from incidence measurement in populations to individual diagnostic use determining recency of HIV-1 infection.
Sedia Biosciences Corporation Raises $500,000 Equity Investment
Strategic China partner to aid in access to new international markets for the company’s epidemiological and diagnostic products.
Sedia Biosciences Announces Global Launch of New Research Assay to Detect Recent HIV-1 Infections
The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a powerful new tool in the global fight against HIV, measures the maturation of the immune response to identify recent HIV infections among those already identified as positive.
News Coverage: New Test Raises Hopes in Global HIV/AIDS Fight
A new test to measure the rate of HIV infection in populations is raising hopes among health officials that they’ll be able to figure out more quickly and cheaply which methods work best to prevent the spread of HIV/AIDS.
Sedia Biosciences Receives NIAID SBIR Grant for New Avidity Assay to Determine HIV-1 Incidence
Phase I funding of the competitive grant is to develop a novel commercial assay to measure host HIV antibody avidity ("binding ability"), an indicator of antibody maturation, which can be used to determine recent vs. long-term HIV-1 infections.
News Coverage: Sedia Readies for Big Test
A Portland-based biotechnology company has a ready-to-go product that’s already in demand worldwide. All the company needs now is a little money to take it to the next level.
News Coverage: Twenty One Oregon Companies Get Millions in Qualifying Therapeutic Discovery Project
Local bioscience company leaders note these new therapeutic discovery funds provide local investment in qualified biomedical projects that show potential to develop new therapies, address unmet medical needs, and reduce the long-term growth of health care costs. DesignMedix, MolecularMD and Sedia Biosciences Corporation are three of the start ups that will receive more than $1.2 million to fund research and discovery.
Want to know more or have any questions? Send us a message!